Home > R&D > Overview


Humanwell has set up five research centers in China, the United States and Europe. In the United States, it has more than 70 approved ANDAs, more than 100 OTC SKUs, and more than 20 drug candidates in various stages of development. The company spends approximately 5% of its revenue in research and development, which ranks it in the top R&D investment group among its domestic pharmaceutical peers. Currently, Humanwell has 218 drugs in development, including 28 new drugs and 9 new chemical entities (NCEs) in various stages of clinical development.




  • 218

    Number of candidates

    Under development

  • 37

    Number of INDs

    In clinical trial

  • 5%

    Percentage of annual

    Revenue earmarked for R&D

  • 1200+

    Number of R&D staff


  • 66

    Number of R&D

    Staff with Ph. D